This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Arkadius Pichota

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO

Arkadius Pichota

less than a year

Tenure

Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.6yrs	€1.10m	0.0036% CHF 85.0k
Arkadius Pichota	Chief Executive Officer	less than a year	no data	no data
Lukas Gilgen	Chief Financial Officer	less than a year	no data	no data
Tim Demuth	Chief Research & Development Officer	1.8yrs	no data	no data
Klaus De Wall	Head of Accounting & Tax	no data	no data	no data
Margit Urban	Head of Discovery Alliances & Technologies	no data	no data	no data
Julia Neugebauer	Head of Investor Relations	no data	no data	no data
Barbara Krebs-Pohl	Chief Business Officer	no data	no data	no data
Günter Wellnhofer	Head of Technical Operations	no data	no data	no data
Harald Watzka	Head of Alliance Management	no data	no data	no data
Yen Ching Chua	Head of Clinical Operations	no data	no data	no data
Kathrin Tissot	Head of Business Team	no data	no data	no data

1.0yrs

Average Tenure

Experienced Management: MOR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Bruce Cheson	Member of Scientific Advisory Board	7.9yrs	no data	no data
Gunther Adolf	Member of Scientific Advisory Board	7.9yrs	no data	no data
Sergio Quezada	Member of Scientific Advisory Board	7.9yrs	no data	no data
Raymond Sweet	Member of Scientific Advisory Board	7.9yrs	no data	no data
Sharon Curran	Independent Member of Supervisory Board	5.2yrs	€92.60k	no data
Heinrich V. Moisa	Chairman of the Supervisory Board	less than a year	no data	no data
Silke Mainka	Member of the Supervisory Board	less than a year	no data	no data
Romain Lege	Deputy Chairman of the Supervisory Board	less than a year	no data	no data

6.5yrs

Average Tenure

51yo

Average Age

Experienced Board: MOR's board of directors are considered experienced (6.5 years average tenure).

This company listing is no longer active

MorphoSys Management

Management criteria checks 1/4

Key information

Recent management updates

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer

MorphoSys AG Appoints Lukas Gilgen as CFO

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

MorphoSys AG Announces Supervisory Board Changes

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer

MorphoSys AG Appoints Lukas Gilgen as CFO

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

First quarter 2024 earnings released: €8.27 loss per share (vs €1.30 loss in 1Q 2023)

Full year 2023 earnings released: €5.53 loss per share (vs €4.42 loss in FY 2022)

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

New minor risk - Shareholder dilution

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings released: €3.50 loss per share (vs €3.60 loss in 3Q 2022)

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €2.16 loss per share (vs €6.88 loss in 2Q 2022)

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings released: €1.30 loss per share (vs €3.59 loss in 1Q 2022)

Full year 2022 earnings released: €4.42 loss per share (vs €15.40 loss in FY 2021)

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

Third quarter 2022 earnings released: €3.60 loss per share (vs €3.30 loss in 3Q 2021)

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Second quarter 2022 earnings released: €6.88 loss per share (vs €0.64 profit in 2Q 2021)

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

First quarter 2022 earnings released: €3.59 loss per share (vs €1.27 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: €3.30 loss per share (vs €2.00 loss in 3Q 2020)

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Second quarter 2021 earnings released: EPS €0.64 (vs €1.62 loss in 2Q 2020)

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

First quarter 2021 earnings released: €1.27 loss per share (vs €6.12 profit in 1Q 2020)

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

Full year 2020 earnings released: EPS €3.01 (vs €3.26 loss in FY 2019)

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

CEO

Tenure

Leadership Team

Average Tenure

Board Members